Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
New Developments Warrant Rethinking HCC Transplant Criteria

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock
Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

April 29th 2025

senior scientist | Image credit: Ohio State University
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Christopher Kane Explains How MRI Is Influencing Prostate Cancer Diagnosis
February 28th 2018

Dr Christopher Kane Explains How MRI Is Influencing Prostate Cancer Diagnosis

Magnetic resonance imaging (MRI) really makes a difference when studying men who’ve had a negative prostate biopsy, but their prostate-specific antigen goes up overtime or something changes and there’s a continuing concern for prostate cancer, said Christopher Kane, MD, professor of urology, University of California, San Diego.
Site Logo
February 28th 2018

Patient-Centered Oncology Care® Recap Issue Now Available

A special issue of Evidence-Based Oncology™ provides full coverage of the conference, which The American Journal of Managed Care® presented November 16-17, 2017, in Philadelphia.
NCCN Releases Guidelines to Address Treatment Gaps for People With HIV and Cancer
February 28th 2018

NCCN Releases Guidelines to Address Treatment Gaps for People With HIV and Cancer

Jaime Rosenberg
The National Comprehensive Cancer Center (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology to help ensure that people living with HIV who are diagnosed with cancer receive safe and necessary treatment.
Site Logo
February 27th 2018

FDA Moves to Era of Active Participant in Drug Development

Mary Caffrey
Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.
Site Logo
February 27th 2018

Building a Culture of Transparency Is Key to FDA in 2018, Experts Say

Alison Rodriguez
Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.
Site Logo
February 27th 2018

Weighing the Merits of Right-to-Try Laws and FDA's Expanded Access Program

Alison Rodriguez Mary Caffrey
Coverage of regulatory changes from Patient-Centered Oncology Care, November 16-17, 2017.
Site Logo
February 27th 2018

Via Oncology's Lokay on Real-World Impact of Digital Decision-Support Solutions

Alison Rodriguez
Coverage of digital technology updates at Patient-Centered Oncology Care, November 16-17, 2017.
Site Logo
February 27th 2018

Panel Addresses Impact of Digital Data Collection and Utilization on Quality Assessment

Alison Rodriguez
Coverage of digital technology updates from Patient-Centered Oncology Care, November 16-17, 2017.
Site Logo
February 27th 2018

Digital Support to Improve Performance Outcomes

Alison Rodriguez
Coverage of digital technology updates from Patient-Centered Oncology Care, November 16-17, 2017.
Site Logo
February 27th 2018

Oncologists Can Save Oncology if They Take Ownership of Costs, Kolodziej Says

Mary Caffrey
Coverage of the Keynote Address from Patient-Centered Oncology Care, November 16-17, 2017.
PFS Recommended as Primary End Point for Phase 2 Immune Checkpoint Inhibitor Trials
February 26th 2018

PFS Recommended as Primary End Point for Phase 2 Immune Checkpoint Inhibitor Trials

Jaime Rosenberg
Traditionally, objective response rate (ORR) is used as the primary end point for phase 2 trials assessing the efficacy of anticancer therapies. However, in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers, progression-free survival (PFS) is recommended as a primary end point over ORR, according to a study published in JAMA Oncology.
Site Logo
February 26th 2018

Medical World News: Clinical/Managed Care Updates

Site Logo
February 26th 2018

Medical World News: Clinical Updates

Site Logo
February 26th 2018

Medical World News: Regulatory Updates

Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment
February 25th 2018

Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment

Kaitlynn Ely
Blood or marrow transplantation (BMT) can have an impact on a patient’s cognitive functioning, affecting a survivor’s ability to integrate with a group of people and return to work. In addition, BMT recipients can experience a weakened memory, a loss of attention and concentration, and difficulty learning.
Kazia Gains Orphan Designation for Investigational Glioblastoma Treatment
February 25th 2018

Kazia Gains Orphan Designation for Investigational Glioblastoma Treatment

Kelly Davio
Kazia Therapeutics Limited, an oncology-focused biotechnology company, announced on Friday that it has received the FDA’s Orphan Drug Designation for its investigational drug, GDC-0084, for the treatment of glioblastoma multiforme, the most aggressive form of primary brain cancer.
Site Logo
February 25th 2018

Future Shock: Embracing Disruption in the Immunotherapy Revolution

Joseph Alvarnas, MD
Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.
Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes
February 24th 2018

Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes

Samantha DiGrande
A study to be published in the Journal of the American College of Surgeons found that a safety-net hospital in Florida could perform an esophagectomy, a highly complex operation, with fewer complications and shorter hospital stays than the national average.
Podcast: This Week in Managed Care—Short-Term Health Plans and Other Health News
February 24th 2018

Podcast: This Week in Managed Care—Short-Term Health Plans and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 24th 2018

Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors

Jaime Rosenberg
Recent study results showed larotrectinib was effective in patients with tropomyosin receptor kinase fusion-positive cancer, regardless of the age of the patient or the tumor type. In addition to implications for the treatment of genetic alterations across tumor types, these study results underscore the importance of molecular profiling of tumors, through which patients were identified for the studies, on ensuring precision medicine is used in practice while simultaneously providing a cost-effective tool.
This Week in Managed Care: February 23, 2018
February 23rd 2018

This Week in Managed Care: February 23, 2018

This week, the top managed care stories included the Trump administration proposed extending the duration of short-term health plans; a report found that CAR T-cell therapies are worth their high price tags; the new issue of Evidence-Based Oncology® examined current issues in immunotherapy.
AJMC® in the Press, February 23, 2018
February 23rd 2018

AJMC® in the Press, February 23, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say
February 22nd 2018

Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say

Jaime Rosenberg
Cell-free DNA derived from liquid biopsy offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and can predict patient survival outcomes for patients with metastatic triple-negative breast cancer, according to a team of researchers.
Site Logo
February 22nd 2018

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

Mary Caffrey
CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Site Logo
February 22nd 2018

Diminished Employment Participation After Breast Cancer Linked to Race and Insurance Status

Kelly Davio
African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg
CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies
February 21st 2018

What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies

AJMC Staff
Research analyzes the cost of processing healthcare bills; supermarket operator Albertsons will buy drugstore chain Rite Aid; a review of phase 1 clinical trials finds just 1 in 10 children with cancer see improvements.
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018

Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission

Laura Joszt, MA
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Site Logo
February 21st 2018

Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

Mary Caffrey
Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.
Site Logo
February 21st 2018

Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry

Samantha DiGrande
Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.
<1
...
535455565758596061
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo